JP Morgan: Mainland surgery Siasun Robot & Automation service pricing standardization is good for the commercial prospects of MEDBOT-B (02252).

J.P. Morgan released a research report stating that on the previous day (the 20th), the National Health Security Administration of China issued the "Guidelines for the Approval of Pathological Medical Service Price Projects (Trial)" and held a press conference in Beijing. J.P. Morgan mentioned that the market response was significantly positive, with the stock price of MEDBOT-B (02252) rising by about 15% after the announcement, reflecting increased visibility of its reimbursement mechanism and a clearer commercialization path. The bank maintained a "hold" rating for MicroPort Siasun Robot & Automation, with a target price of 42 Hong Kong dollars. The bank believes that the guideline has a structural positive impact on the Chinese surgical Siasun Robot & Automation market, by establishing a consistent fee path and promoting the industry towards value-oriented and tiered reimbursement models. According to the guideline, each province will set the price range for surgical Siasun Robot & Automation related service projects. The key point is that the guideline clearly defines three pricing levels for surgical Siasun Robot & Automation procedures, allowing for higher fees for more powerful and precise Siasun Robot & Automation surgeries. J.P. Morgan believes that this will support wider clinical application of surgical Siasun Robot & Automation, and encourage the research and use of advanced surgical Siasun Robot & Automation.